Loading
A phase 1/2 trial of 3H-10000 in gastric & gastro-oesophageal junction cancer, run by 3H Pharmaceuticals Co., Ltd., now recruiting.
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07354711 by 3H Pharmaceuticals Co., Ltd., with 170 participants planned, started 2026-01-04 and due to reach its primary completion in 2028-01. Interventions recorded: 3H-10000.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/